Table 2.
Effect of high-intensity cytarabine containing regimen and ASCT in CR1 on survival stratified by karyotypic complexity
| Patients | Overall Survival | Progression Free Survival | ||||||
|---|---|---|---|---|---|---|---|---|
| High intensity | Low intensity | High intensity | Low intensity | p | High intensity | Low intensity | p | |
| CK | 28 | 24 | 4.5 | 3.8 | 0.8199 | 2.3 | 1.5 | 0.3495 |
| nonCK | 91 | 104 | 11.6 | NR | 0.8789 | 7.8 | 3.1 | 0.0025 |
| ASCT in CR1 | no ASCT | ASCT in CR1 | no ASCT | p | ASCT in CR1 | no ASCT | p | |
| CK | 21 | 13 | 5.1 | 4 | 0.2994 | 3.5 | 1.2 | 0.0823 |
| nonCK | 91 | 95 | 8.6 | NR | 0.9267 | 6.7 | 2.9 | 0.0044 |
High intensity: R-HCVAD, R-MCHOP, R-CHOP/R-DHAP, Nordic Regimin
Low intensity: All others
“Other” regimens not included in analysis